Breast implant adverse events during mammography: Reports to the food and drug administration

被引:6
|
作者
Middleton, MS [1 ]
机构
[1] Univ Calif San Diego, Sch Med, Dept Radiol, San Diego, CA 92103 USA
关键词
D O I
10.1089/154099904323087051
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: To characterize reports of adverse events occurring during mammography to women with breast implants submitted to the Food and Drug Administration (FDA). Methods: We searched the adverse events database for any report on silicone gel breast implants or saline breast implants that included the word "mammography" or "mammogram" in the text. We also searched adverse event reports for mammographic equipment that included the term "breast implant" in the text. Results: We retrieved 714 adverse event reports using this strategy. Sixty-six of these reports detailed an adverse event that occurred during mammography or described breast implant interference with mammography. The majority of these reports, 41 of 66 (62.1%), described breast implant rupture during mammography. Other adverse events reported included mammographic compression crushing implants, pain during mammography attributed to implants, inability to perform mammography because of capsular contracture or fear of implant rupture, and delayed detection of cancer attributed to implants. Conclusions: It is important that women considering breast implants be informed of these potential risks and that clinicians, radiologists, and mammographic technicians keep them in mind when imaging women with implants. © Mary Ann Liebert, Inc.
引用
收藏
页码:379 / 380
页数:2
相关论文
共 50 条
  • [41] Data mining for signal detection of adverse events for taxanes based on the food and drug administration adverse drug events reporting system database
    Wang, Lin-Yu
    Liao, Liu-Feng
    Lei, Cai-Lu
    Wu, Qiong
    Guo, You-Jia
    Li, Yan
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (09) : 833 - 839
  • [42] Processing and evaluation of adverse drug experience reports at the Food and Drug Administration Center for Veterinary Medicine
    Keller, WC
    Bataller, N
    Oeller, DS
    JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 1998, 213 (02) : 208 - 211
  • [43] Adverse Events Associated with Microinvasive Glaucoma Surgery Reported to the Food and Drug Administration
    Duong, Andrew T.
    Yuan, Melissa
    Koenig, Lisa R.
    Rodriguez, Geoffrey H.
    Van Tassel, Sarah H.
    OPHTHALMOLOGY GLAUCOMA, 2021, 4 (04): : 433 - 435
  • [44] Analysis of adverse events with sclerosants reported to the United States Food and Drug Administration
    Nguyen, Christopher N.
    Nguyen, Quoc-Bao D.
    Silapunt, Sirunya
    PHLEBOLOGY, 2022, 37 (06) : 452 - 459
  • [45] Analysis of adverse events with sclerosants reported to the United States Food and Drug Administration
    Nguyen, Christopher
    Quoc-Bao Nguyen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB17 - AB17
  • [46] Serious Adverse Drug Reactions Related to Telaprevir: Analysis of Food and Drug Administration Reported Events
    Love, Bryan L.
    Arabyat, Rasha
    Garg, Vishvas
    Raisch, Dennis W.
    Bennett, Charles L.
    HEPATOLOGY, 2013, 58 : 1100A - 1100A
  • [47] Influence of attitudes on pharmacists' intention to report serious adverse drug events to the Food and Drug Administration
    Gavaza, Paul
    Brown, Carolyn M.
    Lawson, Kenneth A.
    Rascati, Karen L.
    Wilson, James P.
    Steinhardt, Mary
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (01) : 143 - 152
  • [48] Serious Adverse Drug Reactions Related to Boceprevir: Analysis of Food and Drug Administration Reported Events
    Love, Bryan L.
    Garg, Vishvas
    Arabyat, Rasha
    Raisch, Dennis W.
    Bennett, Charles L.
    HEPATOLOGY, 2013, 58 : 228A - 228A
  • [49] Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS)
    Evoy, Kirk E.
    Covvey, Jordan R.
    Peckham, Alyssa M.
    Ochs, Leslie
    Hultgren, Kyle E.
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2019, 15 (08): : 953 - 958
  • [50] Drug Manufacturers' Delayed Disclosure of Serious and Unexpected Adverse Events to the US Food and Drug Administration
    Ma, Paul
    Marinovic, Ivan
    Karaca-Mandic, Pinar
    JAMA INTERNAL MEDICINE, 2015, 175 (09) : 1565 - 1566